George Lagergren wrote:
COMMENT:
Snake oil. From a company that does "reflex testing", sells Willard
water, and does "body scans" (no CT or MRI involved).
The Standard Process products contain "whole foods." And they would
dearly like you to believe the vitamins are extracted or entirely
derived from whole foods. If you don't read the fine print. No vitamin
company gets their vitamins from foods. No vitamin company could afford
to.
Vitamin "B4" was a scientific mistake, and no such thing exists
(anymore than B7. B8, B9, B10, or B-11. Or B13 or 15).
There is no vitamin E-2 or E-3, just various vitamers of vitamin E,
don't have numbers. And finally, since vitamin E as d-alpha tocopherol
increased heart failure in the HOPE trial, and did no good for the
otherwise, it's the LAST thing you'd want to take if you had heart
failure.
Diabetes Care. 2002 Nov;25(11):1919-27.
Effects of vitamin E on cardiovascular and microvascular outcomes in
high-risk patients with diabetes: results of the HOPE study and
MICRO-HOPE substudy.
Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais
G, Mann JF, Gerstein HC; HOPE Study; MICRO-HOPE Study.
Department of Medicine and Population Health Institute, McMaster
University, Hamilton, Ontario, Canada. lonnem@mcmaster.ca
OBJECTIVES: Experimental and observational studies suggest that vitamin
E may reduce the risk of cardiovascular (CV) events and of
microvascular complications in people with diabetes. However, data from
randomized clinical trials are limited. Therefore, we evaluated the
effects of vitamin E supplementation on major CV outcomes and on the
development of nephropathy in people with diabetes. RESEARCH DESIGN AND
METHODS: The Heart Outcomes Prevention Evaluation (HOPE) trial is a
randomized clinical trial with a 2 x 2 factorial design, which
evaluated the effects of vitamin E and of ramipril in patients at high
risk for CV events. Patients were eligible for the study if they were
55 years or older and if they had CV disease or diabetes with at least
one additional coronary risk factor. The study was designed to recruit
a large number of people with diabetes, and the analyses of the effects
of vitamin E in this group were replanned. Patients were randomly
allocated to daily treatment with 400 IU vitamin E and with 10 mg
ramipril or their respective placebos and were followed
for an average of 4.5 years. The primary study outcome was the
composite of
myocardial infarction, stroke, or CV death. Secondary outcomes included
total mortality, hospitalizations for heart failure, hospitalizations
for unstable angina, revascularizations, and overt nephropathy.
RESULTS: There were 3,654 people with diabetes. Vitamin E had a neutral
effect on the primary study outcome (relative risk = 1.03, 95% CI
0.88-1.21; P = 0.70), on each component of the composite primary
outcome, and on all predefined secondary outcomes.
CONCLUSIONS: The daily administration of 400 IU vitamin E for an
average of 4.5 years to middle-aged and elderly people with diabetes
and CV disease and/or additional coronary risk factor(s) has no effect
on CV outcomes or nephropathy.
Publication Types:
Clinical Trial
Multicenter Study
Randomized Controlled Trial
PMID: 12401733 [PubMed - indexed for MEDLINE]
